Jazz Pharmaceuticals agreed to acquire privately held Actio Biosciences for $820 million upfront with up to $500 million in contingent milestone payments. "We started Actio with one goal in mind: to bring meaningful therapies to those who need them most. Moelis & Company LLC is serving as financial advisor to Jazz, with Hogan Lovells Cadwalader US LLP as legal advisor. J.P. Morgan Securities LLC and Centerview Partners LLC are advising Actio Biosciences on the financial side, with Cooley LLP serving as legal advisor.1What is ABS-1230? "The emerging clinical profile of ABS-1230 is highly encouraging, and we look forward to closing the proposed transaction and collaborating with our new Actio Biosciences colleagues to address an urgent patient need.